WaveMan
WaveMan · Company
OCUL · Ocular Therapeutix, Inc
> Search tickers & screens ⌘K
LIVE
← All companies

OCUL Ocular Therapeutix (OCUL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001393434
Quote by TradingView
Form 144 · 8
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
138
13F, latest reported quarter

What the filings say about OCUL

Insiders, 180 days
-$927.9K net sold
7 sellers · 54% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$567.5K
8 notices

Ocular Therapeutix insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, OCULAR THERAPEUTIX, INC insiders sold a net $927.9K of stock across 101 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Anderman Todd
Chief Legal Officer
SELL
2026-10-13 SECtraded 2026-10-08
11,984
$87.4K
-10.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Oct 8, 2025.
  • The trade is 8.5% of the 140,484 shares held after it.
  • 2 other insiders sold within 30 days.
  • 138 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Anderman Todd sold about $87.4K of OCUL under a 10b5-1 plan on Oct 8, 2026; 2 other insiders sold within 30 days and 138 funds added in the latest 13F quarter.
Kaiser Peter
Chief Development Officer
SELL
2026-10-06 SECtraded 2026-10-02
9,990
$70.4K
-10.5%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Aug 24, 2026.
  • The trade is 3.9% of the 254,388 shares held after it.
  • 2 other insiders sold within 30 days.
  • 138 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Development Officer Kaiser Peter sold about $70.4K of OCUL under a 10b5-1 plan on Oct 2, 2026; 2 other insiders sold within 30 days and 138 funds added in the latest 13F quarter.
Heier Jeffrey S.
Chief Scientific Officer
SELL
2026-10-06 SECtraded 2026-10-02
10,869
$76.6K
-10.5%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (1 buy, 9 sales), the last on Aug 24, 2026.
  • The trade is 3.5% of the 307,457 shares held after it.
  • 2 other insiders sold within 30 days.
  • 138 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Heier Jeffrey S. sold about $76.6K of OCUL under a 10b5-1 plan on Oct 2, 2026; 2 other insiders sold within 30 days and 138 funds added in the latest 13F quarter.
Notman Donald
Chief Operating Officer
SELL
2026-09-02 SECtraded 2026-08-31
1,099
$11.3K
-39.2%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Feb 12, 2026.
  • The trade is 0.3% of the 366,529 shares held after it.
  • 4 other insiders sold within 30 days.
  • 138 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Notman Donald sold about $11.3K of OCUL on Aug 31, 2026; 4 other insiders sold within 30 days and 138 funds added in the latest 13F quarter.
Dugel Pravin
See Remarks
SELL
2026-08-26 SECtraded 2026-08-24
21,649
$233.2K
-40.2%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on May 26, 2026.
  • The trade is 0.9% of the 2,525,429 shares held after it.
  • 4 other insiders sold within 30 days.
  • 138 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Dugel Pravin sold about $233.2K of OCUL under a 10b5-1 plan on Aug 24, 2026; 4 other insiders sold within 30 days and 138 funds added in the latest 13F quarter.
101 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 96 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$927.9K over 180 days
-$567.5K over 90 days
below 61% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
138 funds bought in last quarter
more than 80% of Pharma & Biotech
Revenue
-18.5% year over year
below 69% of Pharma & Biotech
Margin
-511.9% net margin
below 78% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
15.6% of the float short (float per yahoo 2026-10-27) · 8.1 days to cover · settled 2026-10-15
more than 81% of Pharma & Biotech
What changed in the last 30 days
Oct 13Chief Legal Officer Anderman Todd sold $87.4K under a 10b5-1 plan (Oct 8)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 8Officer TODD ANDERMAN filed to sell $87.3K by Oct 8 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 6Chief Scientific Officer Heier Jeffrey S. sold $76.6K under a 10b5-1 plan (Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2Officer JEFFREY S. HEIER filed to sell $76.6K by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 2Officer PETER KAZUO KAISER filed to sell $70.5K by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch OCUL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-43.4%12M
-45%-16%+12%+41%2025-102025-122026-022026-042026-062026-082026-10 2026-02-12 · Dugel Pravin sold $1.1M2026-02-20 · LINDSTROM RICHARD L MD bought $461.4K2025-11-05 · Saroj Namrata sold $277.8K2025-11-24 · Dugel Pravin sold $235.1K2026-08-24 · Dugel Pravin sold $233.2K2026-05-26 · Dugel Pravin sold $173.5K2026-02-23 · Dugel Pravin sold $166.1K2026-06-03 · Waheed Nadia sold $122.6K2026-02-12 · Notman Donald sold $103.5K2026-02-12 · Nayak Sanjay sold $93.5K2026-10-08 · Anderman Todd sold $87.4K2026-10-02 · Heier Jeffrey S. sold $76.6K2026-02-12 · Waheed Nadia sold $71.1K2026-10-02 · Kaiser Peter sold $70.4K2026-02-04 · Notman Donald sold $51.5K2026-02-02 · Notman Donald sold $49.9K2025-11-24 · Heier Jeffrey S. sold $41.8K2025-11-24 · Kaiser Peter sold $36.1K2026-08-24 · Heier Jeffrey S. sold $35.5K2026-08-24 · Kaiser Peter sold $32.7K2026-02-20 · Waheed Nadia sold $27.2K2026-02-23 · Heier Jeffrey S. sold $25.3K2026-05-26 · Heier Jeffrey S. sold $24.7K2026-05-26 · Kaiser Peter sold $24.3K2026-02-23 · Kaiser Peter sold $23.3K2025-11-24 · Nayak Sanjay sold $22.6K2026-08-24 · Nayak Sanjay sold $20.4K2026-05-26 · Nayak Sanjay sold $15.2K2026-02-23 · Nayak Sanjay sold $14.6K2026-08-31 · Notman Donald sold $11.3K2026-10-08 · TODD ANDERMAN filed to sell $87.3K2026-10-02 · JEFFREY S. HEIER filed to sell $76.6K2026-10-02 · PETER KAZUO KAISER filed to sell $70.5K2026-08-31 · DONALD D NOTMAN JR. filed to sell $11.3K2026-08-24 · PRAVIN DUGEL filed to sell $233.2K2026-08-24 · JEFFREY S. HEIER filed to sell $35.5K2026-08-24 · PETER KAZUO KAISER filed to sell $32.7K2026-08-24 · SANJAY NAYAK filed to sell $20.5K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns OCUL: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
32,844,043 sh
$322.5M
Deep Track Capital, LP
19,686,282 sh
$193.3M
BlackRock, Inc.
19,376,555 sh
$190.3M
Avoro Capital Advisors LLC
12,540,000 sh
$123.1M
Summer Road LLC
12,208,296 sh
$119.9M

Congress trades in OCUL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

OCUL planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
TODD ANDERMAN
Filed 2026-10-08
$87.3K
JEFFREY S. HEIER
Filed 2026-10-02
$76.6K
PETER KAZUO KAISER
Filed 2026-10-02
$70.5K
DONALD D NOTMAN JR.
Filed 2026-08-31
$11.3K
PRAVIN DUGEL
Filed 2026-08-24
$233.2K

OCUL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Pharmaceuticals ETF
$12.2M position · as of 2026-07-31
2.6%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$7.3M position · as of 2026-06-30
1.7%
PROFUND VP PHARMACEUTICALS
$191.5K position · as of 2026-06-30
1.7%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$219.6K position · as of 2026-07-31
1.1%
Simplify Propel Opportunities ETF
$795.9K position · as of 2026-06-30
1.0%
1290 Essex Small Cap Growth Fund
$966.9K position · as of 2026-07-31
0.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
15 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 1
0 active
3
Phase 2
0 active
6
Phase 3
4 active
1
Early Phase 1
0 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $927.9K sold by insiders over 180 days, 138 funds added last quarter, $567.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

OCUL financials

Revenue growth
-18.5%
XBRL, annual
Net margin
-511.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$52.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-579.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$255.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.02x
long-term debt only, 2023-12-31 (30 months older than the period end); equity 2026-06-30
Cash flow to debt
-26.07x
TTM operating cash flow over long-term debt only, 2023-12-31 (30 months older than the period end)
Return on equity
-73.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-53.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-60.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$831.4M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
FCF yield
-18.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$52.0M$63.7M$58.4M$51.5M
Operating income-$270.0M-$171.8M-$82.4M-$78.7M
Net income-$265.9M-$193.5M-$80.7M-$71.0M
EPS (diluted)-1.42-1.22-1.02-0.97
Operating cash flow-$204.9M-$134.7M-$70.2M-$59.6M
Cash$737.1M$392.1M$195.8M$102.3M
Long-term debtn/an/a$9.1M$28.7M
SEC XBRL, fiscal years, as known on 2026-10-28

OCUL Stock Sonar score 6/7 axes

Find similar shapesCompare

OCUL ranks highest on institutional and government (80th percentile) and financial health (45th), and lowest on risk and compliance (20th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
42
Inputs
  • Return on equity-73.0% · 42 pct, sector of 545
  • Return on assets-53.7% · 42 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-60.9% · 42 pct, sector of 576
Financial health
45
Inputs
  • Debt to equity0.02x · 73 pct, sector of 352
  • Cash flow to debt-26.07x · 17 pct, sector of 371
Growth
31
Inputs
  • Revenue growth, YoY-18.5% · 31 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
22
Inputs
  • Net Form 4 buying (codes P and S), 180d-$372K · 44 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
80
Inputs
  • Funds adding, latest quarter138 · 80 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
20
Inputs
  • Short interest, % of float+15.6% · 23 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+20.1% · 16 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

OCUL filings, in plain words

Are Ocular Therapeutix insiders buying or selling OCUL?

In the 180 days to 2026-10-28, Ocular Therapeutix insiders were net sellers, a net $927.9K across purchases and sales reported on Form 4, by 7 sellers.

Are there planned insider sales of OCUL?

Yes. 8 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $567.5K of stock; the latest, by TODD ANDERMAN, was filed 2026-10-08.

Read the full summary

In the 180 days to 2026-10-28, Ocular Therapeutix insiders were net sellers of OCUL, a net $927.9K across purchases and sales reported on Form 4 by 7 sellers. 54% of the 13 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 8 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $567.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies